Drug Profile
PH 797804
Alternative Names: PH-797804Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antirheumatics; Benzamides; Pyrones; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Musculoskeletal pain; Neuropathic pain; Rheumatoid arthritis
Most Recent Events
- 07 Aug 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Combination therapy) in Argentina (PO)
- 07 Aug 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Combination therapy) in Australia (PO)
- 07 Aug 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Combination therapy) in Bulgaria (PO)